| Title |
Pediatric papillary thyroid cancer: current management challenges
|
|---|---|
| Published in |
OncoTargets and therapy, December 2016
|
| DOI | 10.2147/ott.s100512 |
| Pubmed ID | |
| Authors |
Frederik A Verburg, Hanneke M Van Santen, Markus Luster |
| Abstract |
Although with a standardized incidence of 0.54 cases per 100,000 persons, differentiated thyroid cancer (DTC) is a rare disease in children and adolescents, it nonetheless concerns ~1.4% of all pediatric malignancies. Furthermore, its incidence is rising. Due to the rarity and long survival of pediatric DTC patients, in most areas of treatment little evidence exists. Treatment of pediatric DTC is therefore littered with controversies, many questions therefore remain open regarding the optimal management of pediatric papillary thyroid cancer (PTC), and many challenges remain unsolved. In the present review, we aim to provide an overview of these challenging areas of patient and disease management in pediatric PTC patients. Data on diagnosis, surgery, radionuclide, and endocrine therapy are discussed, and the controversies therein are highlighted. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| China | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 71 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 1 | 1% |
| Unknown | 70 | 99% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 12 | 17% |
| Student > Postgraduate | 11 | 15% |
| Student > Bachelor | 10 | 14% |
| Student > Master | 7 | 10% |
| Student > Ph. D. Student | 6 | 8% |
| Other | 12 | 17% |
| Unknown | 13 | 18% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 40 | 56% |
| Biochemistry, Genetics and Molecular Biology | 6 | 8% |
| Psychology | 3 | 4% |
| Nursing and Health Professions | 2 | 3% |
| Immunology and Microbiology | 2 | 3% |
| Other | 3 | 4% |
| Unknown | 15 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 January 2017.
All research outputs
#17,286,379
of 25,374,917 outputs
Outputs from OncoTargets and therapy
#1,146
of 3,016 outputs
Outputs of similar age
#261,655
of 416,453 outputs
Outputs of similar age from OncoTargets and therapy
#32
of 57 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 21st percentile – i.e., 21% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,016 research outputs from this source. They receive a mean Attention Score of 2.9. This one has gotten more attention than average, scoring higher than 52% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 416,453 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 28th percentile – i.e., 28% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 57 others from the same source and published within six weeks on either side of this one. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.